quick– quick加速器官网
quick– quick加速器官网
Luis
Supply Chain at Apellis
quick– quick加速器官网
Learn More
quick– quick加速器官网
quick– quick加速器官网
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
quick– quick加速器官网
Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)
w加速器官网
Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
@ApellisPharma
quick– quick加速器官网
FOR PATIENTS
quick– quick加速器官网
for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.
quick– quick加速器官网
are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.
CLINICAL TRIALSquick– quick加速器官网
so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike
We challenge conventional thinking and always question if there's a better way.
Join Us
Patricia
Quality Assurance at Apellis
This website is intended for residents of the U.S.